Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 13;12(12):2092.
doi: 10.3390/life12122092.

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC

Asimina Nikolakopoulou  1 , Dimitris Tsakogiannis  2 , Flora Zagouri  3 , Eleni Zografos  3 , Lamprini Tzioga  2 , Grigorios Stratakos  1 , Nikolaos Koulouris  1 , Konstantinos Syrigos  4 , Garyfalia Bletsa  2
Affiliations

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC

Asimina Nikolakopoulou et al. Life (Basel). .

Abstract

Angiopoietin-2 (Ang-2) has been implicated in the development of several types of cancer, including lung malignancy. In the present study, we examined the impact of Ang-2 serum concentration on the development, dissemination, and 5-year overall survival of NSCLC and SCLC. A total of 99 patients with lung cancer were tested. The OS of NSCLC and SCLC patients was estimated using Kaplan−Meier curves and compared through log-rank test. The median serum level of Ang-2 at baseline in both NSCLC and SCLC patients was significantly higher than that of controls (p < 0.0001). The Ang-2 serum concentration was not related to metastasis, neither in NSCLC nor in SCLC cases. The OS was found to be significantly shorter for stage IIIβ NSCLC patients with a high baseline Ang-2 serum concentration (p = 0.012), while Cox regression analysis showed that Ang-2 is a significant independent factor for poor prognosis for stage IIIβ NSCLC (hazard ratio = 2.97, 95% CI: 1.05−8.40, p = 0.04). The concentration of Ang-2 has no impact on the prognosis of SCLC. Ang-2 could be considered as a significant molecular marker that enables the prediction of NSCLC and SCLC development, and is involved in the poor prognosis of stage IIIβ NSCLC.

Keywords: Ang-2; NSCLC; SCLC; angiopoietins; lung cancer; prognostic factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Ang-2 serum levels of healthy controls compared with the Ang-2 serum levels of patients with lung cancer.
Figure 2
Figure 2
Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ lung cancer patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV lung cancer patients with high or low serum Ang-2 at baseline.
Figure 3
Figure 3
Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ NSCLC patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV NSCLC patients with high or low serum Ang-2 at baseline.
Figure 4
Figure 4
Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ SCLC patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV SCLC patients with high or low serum Ang-2 at baseline.
Figure 5
Figure 5
Ang-2 serum levels of patients at the third cycle of chemotherapy. (A) Ang-2 serum levels of NSCLC patients who received PBC in combination with anti-VEGF before treatment and after the third cycle of chemotherapy. (B) Ang-2 serum levels of SCLC patients who received PBC before treatment and after the third cycle of chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Dicker D., Pain A., Hamavid H., Moradi-Lakeh M., MacIntyre M.F., Allen C., Hansen G., Woodbrook R., et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505–527. doi: 10.1001/jamaoncol.2015.0735. - DOI - PMC - PubMed
    1. Torre L.A., Siegel R.L., Jemal A. Lung Cancer Statistics. Adv. Exp. Med. Biol. 2016;893:1–19. doi: 10.1007/978-3-319-24223-1_1. - DOI - PubMed
    1. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., Spitznagel E.L., Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006;24:4539–4544. doi: 10.1200/JCO.2005.04.4859. - DOI - PubMed
    1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008;83:584–594. doi: 10.1016/S0025-6196(11)60735-0. - DOI - PMC - PubMed

LinkOut - more resources